We investigate the conditional power under the framework of linear regression models so that it can be applied to most actual clinical trials in which multiple treatment effects and covariate effects are included. It is well known that the standard power of a regular test for a treatment contrast depends on unknown parameters only through the contrast itself. However it is not true in general for conditional power. Conditions for this to happen are established here and some instances are illustrated. We also show that similar arguments can be made about the sufficient statistics for the conditional power.
Introduction
For ethical and financial reasons, early modifications or in rare cases early termination of the study is often desirable in a long-term clinical trial if the accumulated data during the study has already shown overwhelming evidence of efficacy or the null result seems inevitable. This concern has motivated many statisticians to investigate when and how the accrued data should be examined and under what conditions the clinical trial should be terminated. Such a statistical inferential process performed at interim stages in a trial is called interim analysis. It has attracted more and more attention of both academic and One class of these general methods is identified as group-sequential procedures. Armitage, Mcpherson and Rowe (1969) first introduced a sequential method using repeated significance testing. The idea is that after every observation, a two-sided significance test is conducted. If a nominal significance level  is obtained, stop the trial in favor of the alternative hypothesis. Here  and the maximum number of observations are chosen so that the overall significance level  and the power are maintained at the pre-specified levels. However, this method is criticized for its need for continuous unblinding of the data and assessment after every observation, which is very difficult to meet in practical clinical trials. To circumvent this disadvantage, Pocock (1977) modified Armitage's scheme and proposed a group sequential method in which the data are tested at equally-spaced intervals, that is, after every equally divided group of patients enrolled in the trial. The sample size of each group and the nominal significance are determined to control the overall type I and type II error rate as required. Later, DemMts and Ware (1980) extended Pocock's results to trials with a one-sided hypothesis. Gould (1982) further generalized these procedures by bringing two-end stoping boundaries to allow early termination of a trial with acceptance of null hypothesis. Following the above fundamental contributions on this topic, additional theory has also been developed for more complex models in recent years. Lee and DeMets (1991) obtained group sequential tests for a linear mixed-effects model. Tsiatis (1982) worked on parametric survival models. Gu and Ying(1995) investigated Cox's proportional hazards regression model. Gange and DemMets (1996) considered the sequential analysis of correlated response with non-normal distributions using the generalized estimating equations. For a more comprehensive review of these developments, the interested reader may refer to Jennison and Turnbull (2000) .
In most cases, sequential approaches will require less patients to be enrolled than a fixed sample size design. However, the complexity in design and realization as well as the administrative burden obscured this advantage so that their application are relatively limited in many clinical trials, especially those conducted in multiple centers. Practitioners prefer methods which are simple to be implemented and interpreted. We will not discuss the sequential family further in this paper, turning our main interest to another important class of strategies adopted in interim analysis.
The second cluster of statistical tools arise from a very natural question:"Based on the data accrued so far, what is the likelihood of a significant result if the trial is completed?" Unlike those sequential procedures which are purely driven by interim data, these latter approaches combine the current data and the potential future outcome together. The key consideration lies in the calculation of the conditional power, which is the probability of rejecting the null hypothesis at the planned end of study given the existing data at the interim stages, along with certain speculation about future data. If this probability equals to or exceeds a pre-specified threshold, a termination of the trial is made in favor of or against the null hypothesis. These procedures are called conditional power methods, also well known as stochastic curtailment methods termed by Lan, Simon and Halperin (1982) , who initiated studies on this class.
In their thought-provoking paper, Lan, Simon and Halperin (1982) The simplicity as well as flexibility of the this method is very attractive to practitioners, but it also raises a problem on how to choose the value of the tested parameter  under which the conditional power is calculated. As Pepe and Anderson (1992) has argued, it is debatable for Lan, Simon and Halperin (1982) to compute the conditional power only under the alternative hypothesis  with which is equal to / n S n , the sample mean of the interim data. Pepe and Anderson (1992) considered a similar approach but used a more pessimistic value of ( ) / n S n n  for  . Finally, Betensky (1997) 
S a n n  to obtain a less conservative result. In these three procedures, the conditional probability is independent of the alternative hypothesis. Although many procedures based on conditional power have been developed for interim analysis, possibly for the purpose of convenience, only trials of one or two arms are considered.
In this article, we will discuss the conditional power under the framework of linear regression models so that it can be applied to most actual clinical trials in which multiple treatment effects and covariate effects are included. It is well known that the standard power of a regular test for a treatment contrast depends on unknown parameters only through the contrast itself. However it is not true in general for conditional power. Conditions for this to be true for conditional power are established here and some instances are illustrated. We also show that similar arguments can be made about the sufficient statistics for the conditional power.
Models without covariate effects

Model description and the full analysis plan
Let us start with a commonly used clinical trial discussed by many researchers as listed in the previous section. It consists of two arms, one arm for treatment A and another arm for treatment B. We are interested in comparison of main effects of treatment A and 
Remark 2.1.1
1.
Both type I and type II errors are controlled for any ,
A B
n n as long as
The actual power will be greater than 1 Note: 0 d is set to 0 in the rest of this paper.
Conditional power
At a certain stage during the trial, the interim analysis is performed. Without loss of generality, we assume that the whole study consists of just two stages, stage 1 and stage 2.
Notations:
n n n be the number of observations under treatment i at stage 1, stage 2 and the full study respectively. Let 1 2 , , . So (6) can be written as
Note that 1 D and 2 D are independent. The following theorem is immediate. 1 D is given by
Theorem 2.2.1Under normality assumption, c P , the probability of rejecting the null hypothesis upon completion of the study conditional on the interim data
Further, the following corollary follows immediately. 
Conditional probability on the observed difference
The purpose of the interim analysis is to explore the possibility of early termination of an experiment. This is usually done by examining the difference 1
and carrying out a test for 0 H at that stage. We, therefore, take the view that the conditional probability 
where, 
From (8), we can rewrite T in terms of V and W as (
Then the following useful observations can be made.  are given by 
.
Proof.Note that the joint distribution of W and V is bivariate normal.
Then, (15) and (16) follow.
Fact 2.3.2 If = =
A B n n n , then (15) and (16) can be simplified as
and, 2 2 = ( ) / (2 )( ) . 
where T  is given by (20) .
This can be obtained by the standard delta-method. For completeness, the proof is given in the Appendix. 
where T  is as in (20) . 
which is the sum squares of covariates within arms. 
Obviously, this variance does not depend on  and is minimized when =
A B x x , and remains the same as the one under the model without the covariate.
With (26), the critical value v c and required sample size under this setup can be obtained as 1 0
Remark 3.1.2
1.
Both type 1 and type 2 errors are controlled for any ,
A B
n n as long as 
By comparing (4) with (29) and (5) x x  is appreciably large, then no matter what the sample size is, the expected power will be hard to achieve.
Conditional power
As in the previous section, the conditional power is evaluated when 1 A n and 1 B n patients are enrolled in arms A and B respectively at stage 1.
Notations:
Let 1 2 , ,
n n n be the number of observations under treatment i at stage 1, stage 2 and full study. 
The conditional power, c P , is formulated as 1= ( > | ). 
Before further simplification for (32), let us first introduce the following facts. Proof. Notice that,
and that for 
2.
(33) can also be written as
So from (36), it follows that: (i) ( (33) and (34) respectively. Now it is easy to conclude the following.
Theorem 3.2.1Under the model (24), with normality assumption, c
P , the probability of rejecting null hypothesis upon completion of study conditional on the interim data 1 D is given by D . In practice, we may simplify (40) by making some assumptions or controlling the covariates.
Case 1 If =
A B x x , (40) is simplified to: (1 )
which is independent of  .
Case 2 If
r r r x x x x x x , c P is given by
This result can also be obtained by noting that,  . This is a fairly reasonable assumption in practice.
Case 2.1 In (45), with additional constraints
1 2 = 1 = X X X SS r SS r SS  , c P is given by 1 1 2 2 2 2 1( ) (1 )( ) = ( ) (1 )( ) 1 1 (1 ) ( ) A B A B v c A B A B X r r c P r r x x r n n SS                (47)
Case 2.2 In (45), with additional constraints =
A B x x , c P is given by
which is the same as c P under model without covariates' effect.
Extension to multiple treatments
In practical clinical trials, there are often more than two treatments involved, as in doseresponse finding trials. Therefore, in this section, we extend our work to these situations. We still use the model (24), but k treatments are considered. The model is as follows: = . Without loss of generality, we are interested in comparing the main effects of treatment 1 and treatment 2. As in previous section, the final test will be based on the LS-estimators for i  and  as follows:
Note that the difference between (50) and (25) is that comes from the response in all treatment groups rather than just treatment 1(A) and treatment 2(B), which results in the changes in
as follows: 
where 
Model containing a covariate with possibly different coefficients
Model description and the full analysis plan
In the previous section, we assumed that all treatment groups share the same coefficient, which may not hold in practice. In this section, we do not make that assumption and the model of interest is described below:
where all notations have the same meaning as in (24) 
which is also larger than N in (5) and (30).
Conditional Power
To obtain the conditional power, let us first state the following facts. 
So from (69) and (70), it follows that:
However, as expected,( ) = (1 ) The following theorem is immediately obtained. 
Extension to multiple arms
In case the trial consists of more than two arms, the results about c P remain the same for all pairwise comparisons, taken separately. This is because the existence of other arms have no effects on expressions (62) through (68).
Concluding Remarks
In this paper we have studied some aspects of evaluation of conditional power in the context of interim analysis, involving two stages of analysis, under a simple linear regression model. We have extended available results in the framework of linear regression with / without a common regression parameter. Additional studies involving more than one regressor / other design-set are to be found in the Doctoral Dissertation of Li (UIC, Unpublished Thesis, 2007).
